Welcome!

News Feed Item

The World Market for Immunoassays

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The World Market for Immunoassays

http://www.reportlinker.com/p02076275/The-World-Market-for-Immunoassays.html

The immunoassay market is large and long-established, but at the same time highly competitive. Kalorama Information's newly published report, The World Market for Immunoassays, describes the opportunities that exist for large IVD companies adopting new strategies and for new entrants to take market share.

Immunoassays have been used in clinical laboratory medicine since the 1960s, and are indispensable tools in clinical diagnostics. A wide range of types of immunoassays are now used to measure proteins (including antibodies), hormones, drugs, and other analytes. Fully automated immunoassay systems are now found in clinical laboratories. Even though the field of immunoassays is now mature, companies have continued to develop new immunoassays and immunoassay instrument platforms to further improve the sensitivity of the assays, to make multiplexing possible, to miniaturize the platforms for point-of-care, and to identify and develop assays for novel biomarkers, thus further expanding the potential of immunoassays for the future.

As part of its analysis the report provides:

Trends and innovations, including miniaturization and multiplexed assays
Regional and Emerging Market Opportunities
Novel Biomarkers Detected by Immunoassays
Segments of the Immunoassay Market, by Location of the Testing
Segments of the Immunoassay Market by Analyte Category
Sales for 2012 and Projected to 2017
Profiles of Companies Currently marketing Immunoassays
Profiles of New Companies Entering This Market.
Exhaustive Segment Market Data

Market analysis in this report is broken out into several market segments.

For each segment, current market size, forecast to 2017 and a discussion of the market is included:

Lab-Based Immunoassays
POC Immunoassays
Blood Screening Immunoassays
Fertility/Pregnancy Immunoassays
Thyroid, Metabolic Immunoassays
Therapeutic Drug Monitoring
Drugs of Abuse
Allergy Immunoassays
Autoimmune Immunoassays
PSA Markers
CEA Markers
CA 125 Markers
Other Tumor Markers
Hepatitis Immunoassays
HIV Immunoassays
STD Immunoassays
TORCH
Respiratory Immunoassays
Hospital Acquired Infection Immunoassays
Cardiac Markers
Other

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.
CHAPTER ONE: EXECUTIVE SUMMARY:
Overview
Scope and Methodology
Market Overview
Future Prospects in the Immunoassay Market
CHAPTER TWO: INTRODUCTION
Background
History and Future of Immunoassays
CHAPTER THREE: TECHNOLOGY, TRENDS AND INNOVATIONS
Overview – Immunoassays
Overview – Instrument Platforms
Automation
Platform Innovations –
Miniaturization, Microfluidics and Multiplexed Assays
Specimen Types
Blood
Urine
Saliva
CHAPTER FOUR: MARKET SEGMENTS BY TYPE OF LABORATORY
Centralized Laboratories
Companies Marketing to Centralized Laboratories
Rapid and Point-of-Care Testing
POC Testing in Hospitals
Physicians' Office Laboratories and Clinics
Retail Clinics
Other Professional POC Testing
Self-Testing – Over-the-Counter (OTC) Tests
Companies Marketing Immunoassays for POC Testing
Blood Testing
CHAPTER FIVE: IMMUNOASSAY DIAGNOSTIC MARKET ACTIVITY BY DISEASE CATEGORY
Cardiac Markers
Fertility/Pregnancy/Reproductive Hormones
Thyroid
Metabolic Disorders and Other Hormones
Therapeutic Drug Monitoring
Drugs of Abuse
Allergy
Autoimmune Disease
Other Disease Categories in Immunoassay Disease Market
CHAPTER SIX: MARKET OPPORTUNITIES AND ISSUES FOR IMMUNOASSAYS
Immunoassay Market – Market Drivers and Changes
The Patient Protection and Affordable Care Act
Emerging International Markets
CHAPTER SEVEN: IMMUNOASSAY MARKET ANALYSIS
Market Overview and Market Segments by Type of Laboratory
Lab-Based Immunoassays by Disease Category
Point-of-Care/Rapid Test Immunoassays by Disease Category
Immunoassay Market in Different Geographical Regions
Prognosis for Growth of the Immunoassay Market
CHAPTER EIGHT: COMPANY PROFILES OF COMPANIES MARKETING IMMUNOASSAY SYSTEMS AND TESTS
1 Step Detect Associates, LLC
Abbott Laboratories
Recent Revenue History:
Access Bio, Inc.
AccuBioTech Co., Ltd
Accumed Biology (Shanghai) Co., Ltd.
Accutech, LLC
ACON Laboratories, Inc.
Advanced Biomedical Systems S.r.l. (ABS)
AESKU.DIAGNOSTICS
Akers Biosciences, Inc.
Alere Inc.
Recent Revenue History:
Alfa Scientific Designs, Inc.
ALPCO
Amedica Biotech
American Bio Medica Corporation
Recent Revenue History:
AmniSure International LLC (A Qiagen Company)
Ani Biotech Oy
Apacor Ltd.
ARK Diagnostics Inc
ARKRAY, Inc.
Arlington Scientific, Inc
Artron Laboratories Inc.
Associates of Cape Cod, Inc. (ACC)
Astra Biotech GmbH
Atlas Link, Inc.
Atlas Link Biotech Co., Ltd.
Audit Diagnostics
Augurix SA/Augurix Diagnostics
Autobio Diagnostics Co., Ltd.
Awareness Technology, Inc.
Avioq, Inc.
AXA Diagnostics Srl
Axis-Shield plc (Acquired by Alere)
Company Overview
AZOG, Inc.
Becton, Dickinson and Company (BD)
Beijing Chemclin Biotech Co., Ltd.
BG Medicine, Inc.
Bhat Bio-Tech India Private Ltd. (BBI)
Binding Site Group Ltd. (The)
Biocare Diagnostics Ltd.
BioCheck, Inc.
BIOCLIN
Biohit Oyj (BioHIt Healthcare)
Biokit S.A. (Part of Werfen Group)
bioLytical Laboratories Inc.
Bio-Medical Products Corp.
Biomerica, Inc.
Recent Revenue History
bioMérieux sa
BioPorto Diagnostics A/S
Recent Revenue History
Company Overview
Bio-Rad Laboratories, Inc.
Recent Revenue History
Company Overview
BioScan Screening Systems, Inc.
Bioscience (Tianjin) Diagnostic Technology Co., Ltd.
BioSino Bio-Technology and Science Inc.
Biotech Atlantic, Inc.
Biotron Diagnostics Inc.
Blue Cross Bio-medical Co., Ltd.
BNTX Inc.
Boditech Med Inc.
Boson Biotech Co., Ltd.
Branan Medical Corporation
BÜHLMANN Laboratories AG
Calypte Biomedical Corporation
CARE Diagnostica
CARE Products, Inc.
Cavida AB
CerTest Biotec
Chembio Diagnostics, Inc.
Recent Revenue History
Company Overview
Chemtron Biotech, Inc
Cisbio Bioassays
Clarity Diagnostics (Diagnostic Test Group, LLC)
Clinical Innovations, LLC
CONCATENO (Subsidiary of Alere)
Confirm Biosciences
ContraVac, Inc.
Core Technology Co., Ltd.
Corgenix Medical Corporation
Recent Revenue History
Company Overview
Coris BioConcept
CTK Biotech, Inc.
Denka Seiken Co., Ltd.
Devon Medical Products
DFI Co., Ltd
diaDexus, Inc.
Company Overview
Diagenics International Corporation
Diagnosticum Inc.
DIALAB GmbH
Diametra
DiaSorin S.p.A.
Recent Revenue History
Company Overview
DIAsource ImmunoAssays
DiaSys Diagnostic Systems
Diaxonhit
Diazyme Laboratories
DIESSE Diagnostica Senese S.p.A
Dr. Fooke Laboratorien GmbH
DRG International, Inc.
D-tek s.a.
Eiken Chemical Co., Ltd.
EKF Diagnostics Holdings plc
Recent Revenue History
Company Overview
Embryotech Laboratories
ERBA Diagnostics, Inc.
Recent Revenue History
Company Overview
Euroimmun AG
Eurospital Spa
EY Laboratories, Inc.
First Check Diagnostics Corp. (Subsidiary of Alere)
Focus Diagnostics, Inc. (Subsidiary of Quest Diagnostics Inc.)
Fujirebio Inc.
Recent Revenue History
Company Overview
Germaine Laboratories
GlysBy
Gold Standard Diagnostics Corporation
Grifols International S.A.
Company Overview
Hema Diagnostic Systems, LLC (HDS)
Hemosure, Inc.
Hightop Biotech Co., Ltd
Hipro Biotechnology Co., Ltd.
HYCOR Biomedical, Inc.
IDenta Corporation
IMMCO Diagnostics, Inc. (Acquired by Trinity Biotech)
Immunetics, Inc.
Immunodiagnostic Systems Ltd. (IDS)
Recent Revenue History
Company Overview
Immunomedics, Inc
Immuno-Mycologics, Inc.
ImmunoScience, Inc.
Immunostics, Inc.
InBios International, Inc.
INOVA Diagnostics, Inc. (Part of Werfen Group S.A.)
Instant Technologies, Inc
InTec Products, Inc.
International Immuno-Diagnostics
Jant Pharmacal Corporation
Jei Daniel Biotech Corp.
j. Mitra & Co.Pvt. Ltd.
Kronus
Lab 21 Limited
Labor Diagnostika Nord GMBH & CO. KG
Labsystems Diagnostics Group
Labtest
Lepu Medical Technology (Beijing) Co. Ltd.
LifeAssays AB
LifeSign LLC
Liming Bio-Products Co., Ltd
Luminex Corporation
Recent Revenue History
Company Overview
MagnaBioSciences, LLC
MAVAND Solutions GmbH
Medipan GmbH
Medisensor, Inc.
Mediwatch Plc
Medix Biochemica
Recent Revenue History
Mercodia AB
Recent Revenue History
Micropoint Bioscience, Inc.
Mitsubishi Chemical Medience Corporation
Monobind Inc.
MP Biomedicals, LLC
Nano-Ditech Corporation
Nantong Egens Biotechnology Co., Ltd.
National Test Systems (Formerly QuikTest USA, Inc.)
NewScen Coast Bio-Pharmaceutical Co., Ltd.
NexScreen LLC
Nobel Medical Inc.
Novatec Immundiagnostica GmbH
Oasis Diagnostics Corporation
Omega Diagnostics Group PLC
Oncimmune Ltd.
Operon
OraSure Technologies, Inc.
Recent Revenue History
Company Overview
Orgentec Diagnostika GmbH
Ortho-Clinical Diagnostics
Recent Revenue History
Company Overview
Pan Probe Biotech, Inc.
Perfemed Group
Pharmatech, Inc.
Pointe Scientific, Inc.
Polymedco, Inc.
Polymed Therapeutics, Inc.
Precheck Bio, Inc.
Prestige Diagnostics
Preventis GmbH
Princeton Biomeditech Corporation
Pro-Lab Diagnostics Inc.
Qualigen, Inc.
Recent Revenue History
Company Overview
Radiometer Medical ApS
Recent Revenue History
Company Overview
Randox Laboratories Ltd
Rapid Pathogen Screening, Inc.
R-Biopharm AG
Reagena Group
Real World Diagnostics
Redwood Toxicology Laboratory, Inc.
ReLIA Diagnostics, Inc.
RENESA UG
Response Biomedical Corporation
Recent Revenue History
Company Overview
Reszon Diagnostics International Sdn. Bhd.
Roche Diagnostics
Recent Revenue History
Company Overview
SA Scientific
Savyon Diagnostics
ScheBo-Biotech AG
Screening Devices Canada, Inc.
Sekisui Diagnostics, LLC
Serascience
Shanghai Kehua Bio-engineering Co., Ltd.
Shanghai Upper Biotech
Sichuan Maker Biotechnology Co., Ltd.
Company Overview
(Shenzhen New Industries Biomedical Engineering Co., Ltd.)
Span Diagnostics Ltd.
Standard Diagnostics (Part of Alere)
SureScreen Diagnostics
Syntron Bioresearch, Inc.
Systagenix Wound Management
TECHLAB, Inc.
Teco Diagnostics
Theradiag
Company Overview
Bio-Enoche Group, LLC
Tosoh Corporation
Company Overview
Transasia Bio-Medicals Ltd.
Trinity Biotech plc
True Diagnostics, Inc.
Turklab Medical Devices Inc.
UCP Biosciences, Inc.
US Diagnostics, Inc.
VEDA.LAB SA
Vircell S.L.
Vital Diagnostics, Inc. (An ELITech Group Company)
Recent Revenue History
Company Overview
Wako Diagnostics
WAMA Diagnostica
Werfen Group
Recent Revenue History
Company Overview
Wiener Laboratorios S.A.I.C.
Zhuhai Encode Medical Engineering Co., Ltd.
ZEUS Scientific, Inc.
CHAPTER NINE: NEW ENTRANTS
Akrivis Technologies, LLC
Alverix, Inc.
Amorfix Life Sciences Ltd.
Arbor Vita Corporation
Athera Biotechnologies
Atlas Genetics Ltd
Atonomics A/S
Augurex Life Sciences Corp.
Avant Diagnostics, Inc.
Axela, Inc.
AXO Science
Banyan Biomarkers
Biocartis SA
BioMedomics
BioMosaics
Biophor Diagnostics
Biosensia Ltd.
BioSystems International
Boulder Diagnostics
CardioGenics Holdings, Inc.
CD Diagnostics, Inc.
Cellmid Ltd.
Clearbridge BioLoc Pte Ltd.
Courtagen Life Sciences, Inc.
Crescendo Bioscience
Critical Diagnostics
Cytonics Corporation
CyVek Inc.
EDP Biotech Corporation
Endeavor Power Corp.
Epinex Diagnostics, Inc.
Epocal, Inc.
Eveia Medical, Inc.
Gamma Therapeutics, Inc.
Genalyte, Inc.
GeneFluidics, Inc
Genisphere, LLC
Gentag, Inc
HealthLinx Limited
ImCare BioTech
Innovative Health Diagnostics
Intrinsic LifeSciences
MagArray, Inc.
Magnisense SE
Martell Diagnostic Laboratories, Inc.
MBio Diagnostics, Inc.
Nanomix, Inc.
Ohmx Corporation
O-J-Bio Ltd.
OncoHealth Corporation
OPKU Health, Inc./OPKU Diagnostics
Protagen AG
Quanterix Corporation
Siloam Biosciences, Inc.
Singulex, Inc.
SQi Diagnostics Inc.
STAT-Diagnostica
Sword Diagnostics
T2 Biosystems, Inc.
Venaxis, Inc.
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1: Immunoassay Sales
Table 1-1: Immunoassay Sales (Lab-Based, POC, Blood Screening)
Figure 1-1: Immunoassay Sales Trend By Type (Lab Based, POC, Blood Screening)
CHAPTER THREE: TECHNOLOGY, TRENDS AND INNOVATIONS
Table 3-1: Selected Innovations in Immunoassay Platforms
Table 3-2: Selected Companies with Saliva or Oral-Fluid Collection Devices
CHAPTER FOUR: MARKET SEGMENTS BY TYPE OF LABORATORY
Table 4-1: Selected Companies Marketing Central Lab-Based Immunoassays
Table 4-2: Selected Companies Marketing Immunoassays and/or Lateral Flow Tests for Point-of-Care Testing
Table 4-3: Selected Companies Marketing Immunoassay Platforms for Blood Screening
CHAPTER FIVE: MARKET SEGMENTS BY TYPE OF LABORATORY
Table 5-1: Immunoassay Market Disease Categories
Table 5-2: Selected Infectious Disease Immunoassays
Table 5-3: Selected Companies Marketing Immunoassays for Infectious Diseases
Table 5-4: Selected Tumor Marker Immunoassays
Table 5-5: Selected Companies Marketing Immunoassays for Tumor Markers
Table 5-6: Selected Cardiac Marker Immunoassays
Table 5-7: Selected Companies Marketing Immunoassays for Cardiac Markers
Table 5-8: Selected Fertility and Reproductive Hormone Immunoassays
Table 5-9: Selected Companies Marketing Immunoassays Fertility/Pregnancy/Reproductive Hormone Diagnostics
Table 5-10: Selected Thyroid Immunoassays
Table 5-11: Selected Companies Marketing Immunoassays for Thyroid Diagnostics
Table 5-12: Selected Metabolic and Other Hormone Immunoassays
Table 5-13: Selected Companies Marketing Immunoassays for Metabolic/Other (Non-Reproductive, Non-Thyroid) Hormone Diagnostics
Table 5-14: Selected Therapeutic Drug Monitoring Immunoassays
Table 5-15: Selected Companies Marketing Immunoassays for Therapeutic Drug Monitoring
Table 5-16: Selected Drugs of Abuse Assays
Table 5-17: Selected Companies Marketing Immunoassays for Drugs of Abuse
Table 5-18: Selected Allergy Diagnostic Tests
Table 5-19: Selected Companies Marketing Immunoassays for Allergy Diagnostics
CHAPTER SEVEN: MARKET OPPORTUNITIES AND ISSUES FOR IMMUNOASSAYS
Table 7-1: Immunoassay Sales by Type of Laboratory Worldwide, 2012 and 2017 (Lab-Based, OTC, Prof. POC, Blood Screening)
Table 7-2: Revenue History of Leading Immunoassay Vendors*, 2010-2012
Table 7-3: Lab-Based Immunoassay Sales by Disease Category (Infectious Disease, Tumor Markers, Cardiac Markers, Fertility/Pregnancy, Thyroid, Metabolic, Therapeutic Drug Monitoring, Drugs of Abuse, Allergy, Autoimmune, Other) Worldwide, 2012 and 2017
Table 7-4: Lab-Based Infectious Disease Immunoassay Sales Worldwide, 2012 (Hepatitis, HIV, STD, TORCH, Respiratory, HAIs, Other)
Table 7-5: Lab-Based Tumor Marker Immunoassay Sales Worldwide, 2012 (PSA, CEA, CA 125, AFP, Other)
Table 7-6: Point-of-Care/Rapid Immunoassay Sales by Disease Category (Pregnancy, Infectious Disease, Cancer, Cardiac Markers, Drugs of Abuse, Other) Worldwide, 2012 and 2017
Table 7-7: Immunoassay Sales by Geographic Region (North America, Europe, Japan, Rest of World) Worldwide, 2012 and 2017

To order this report: The World Market for Immunoassays
http://www.reportlinker.com/p02076275/The-World-Market-for-Immunoassays.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.